Nordic Capital Partners with Evosep to Transform Proteomics
Nordic Capital has taken a significant step by announcing its majority ownership of Evosep, a prominent Danish innovator in proteomics solutions. This strategic investment is set to leverage Nordic Capital's extensive experience in healthcare and the life sciences sector, cultivated over decades of commitment. The collaboration aims to accelerate Evosep's global growth while enhancing its cutting-edge workflows and analytical capabilities.
About Evosep and Its Impact on Proteomics
Founded in 2016, Evosep stands out for its innovative technology that allows for rapid and robust protein analysis. The firm specializes in developing advanced instruments and consumables tailored for liquid chromatography-mass spectrometry (LC-MS) based proteomics. By simplifying complex processes, Evosep empowers laboratories to derive deeper biological insights and contribute to accelerating medical discoveries that significantly benefit healthcare and life sciences.
Evosep has recognized the growing global demand for high-performance protein analysis, which plays a vital role in biomarker discovery and diagnostic developments. The organization's proficient approach ensures that laboratories obtain consistent and comparable results, ultimately fostering a better understanding of various diseases.
Nordic Capital's Commitment to Healthcare Investments
Nordic Capital's partnership with Evosep is founded on a shared commitment to the healthcare sector. The firm possesses vast expertise across biopharma, medtech, and diagnostics. Significant investments in other successful ventures highlight their dedication, showcasing their role in advancing healthcare solutions worldwide. This collaboration adds another layer to Nordic Capital's impressive portfolio.
Future Goals and Expansion for Evosep
With Nordic Capital's backing, Evosep is poised to enter an exciting growth phase. The partnership will focus on enhancing product development and commercial capabilities to broaden Evosep's market presence. Morten Bern, CEO of Evosep, expressed enthusiasm about the partnership, noting that their mission to revolutionize proteomics will remain steadfast.
This collaboration promises to propel Evosep towards achieving its ambitious goals, including advancing the standardization of LC-MS-based proteomics. Ongoing collaboration with Nordic Capital will support their mission to provide impactful products and solutions to their customers.
Investment Structure and Market Position
The investment is facilitated through Nordic Capital's Evolution platform, which targets middle-market growth companies throughout Northern Europe. The platform aims to apply proven strategies to partner with innovative businesses and create long-term value. Evosep becomes the thirteenth addition to this platform, highlighting booming growth since its establishment.
Continued Collaboration with Founders
As part of this investment, minority shareholders will divest their stakes while the founders, Ole Vorm and Matthias Mann, will continue to be involved in guiding Evosep's strategic direction. This approach ensures continuity and allows for leveraging their extensive knowledge and experience in proteomics technologies.
Looking Ahead After the Investment
While the financial details surrounding the transaction have not been disclosed, it is anticipated that the completion of this agreement will significantly enhance Evosep’s operational capabilities. The expected completion timeframe positions Evosep to make timely advancements in the fast-evolving proteomics field.
Frequently Asked Questions
What is the purpose of Nordic Capital's investment in Evosep?
The investment aims to enhance Evosep's capabilities and accelerate its growth in the global proteomics market.
What technology does Evosep specialize in?
Evosep focuses on liquid chromatography-mass spectrometry (LC-MS) based proteomics, developing advanced instruments and workflows.
When was Evosep founded?
Evosep was founded in 2016 and has made significant contributions to the field of proteomics.
Who are the key contacts at Nordic Capital and Evosep?
Katarina Janerud is the Communications Manager at Nordic Capital, while Christian Ravnsborg serves as VP of Marketing at Evosep.
How will the partnership impact the future of healthcare?
The partnership is expected to enhance diagnostic capabilities, contributing to better healthcare solutions and patient outcomes.
